Cargando…
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with f...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015319/ https://www.ncbi.nlm.nih.gov/pubmed/27604188 http://dx.doi.org/10.1186/s13104-016-2243-8 |
_version_ | 1782452416782794752 |
---|---|
author | Wicks, Paul Rasouliyan, Lawrence Katic, Bo Nafees, Beenish Flood, Emuella Sasané, Rahul |
author_facet | Wicks, Paul Rasouliyan, Lawrence Katic, Bo Nafees, Beenish Flood, Emuella Sasané, Rahul |
author_sort | Wicks, Paul |
collection | PubMed |
description | BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with fingolimod or dimethyl fumarate were recruited from an online patient community and completed an online survey about treatment side effects, discontinuation, and satisfaction. RESULTS: 281 patients in four groups completed the survey: currently receiving fingolimod (CF, N = 61), currently receiving dimethyl fumarate (CDMF, N = 129), discontinued fingolimod (DF, N = 32) and discontinued dimethyl fumarate (DDMF, N = 59). Reasons for treatment switch were to take oral treatment (CF: 63.3 %, CDMF: 61.8 %), side effects of prior medication (CF: 67.3 %, CDMF: 44.1 %) and lack of effectiveness of prior medication (CF: 38.8 %, CDMF: 31.4 %). Main reasons for discontinuation were side effects (DF: 46.9 %, DDMF: 67.8 %) and lack of effectiveness (DF: 25.0 %, DDMF: 15.3 %). CDMF patients had an increased risk of abdominal pain, flushing, diarrhea, and nausea. Treatment satisfaction was highest among CF patients followed by CDMF, DF, and then DDMF patients. CONCLUSIONS: Discontinuation was driven by experience of side effects. Patients currently taking dimethyl fumarate were more likely to experience a side effect versus patients currently taking fingolimod. Examination of the relationship between tolerability and adherence/persistence is needed. |
format | Online Article Text |
id | pubmed-5015319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50153192016-09-09 The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis Wicks, Paul Rasouliyan, Lawrence Katic, Bo Nafees, Beenish Flood, Emuella Sasané, Rahul BMC Res Notes Research Article BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with fingolimod or dimethyl fumarate were recruited from an online patient community and completed an online survey about treatment side effects, discontinuation, and satisfaction. RESULTS: 281 patients in four groups completed the survey: currently receiving fingolimod (CF, N = 61), currently receiving dimethyl fumarate (CDMF, N = 129), discontinued fingolimod (DF, N = 32) and discontinued dimethyl fumarate (DDMF, N = 59). Reasons for treatment switch were to take oral treatment (CF: 63.3 %, CDMF: 61.8 %), side effects of prior medication (CF: 67.3 %, CDMF: 44.1 %) and lack of effectiveness of prior medication (CF: 38.8 %, CDMF: 31.4 %). Main reasons for discontinuation were side effects (DF: 46.9 %, DDMF: 67.8 %) and lack of effectiveness (DF: 25.0 %, DDMF: 15.3 %). CDMF patients had an increased risk of abdominal pain, flushing, diarrhea, and nausea. Treatment satisfaction was highest among CF patients followed by CDMF, DF, and then DDMF patients. CONCLUSIONS: Discontinuation was driven by experience of side effects. Patients currently taking dimethyl fumarate were more likely to experience a side effect versus patients currently taking fingolimod. Examination of the relationship between tolerability and adherence/persistence is needed. BioMed Central 2016-09-07 /pmc/articles/PMC5015319/ /pubmed/27604188 http://dx.doi.org/10.1186/s13104-016-2243-8 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wicks, Paul Rasouliyan, Lawrence Katic, Bo Nafees, Beenish Flood, Emuella Sasané, Rahul The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis |
title | The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis |
title_full | The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis |
title_fullStr | The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis |
title_full_unstemmed | The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis |
title_short | The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis |
title_sort | real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015319/ https://www.ncbi.nlm.nih.gov/pubmed/27604188 http://dx.doi.org/10.1186/s13104-016-2243-8 |
work_keys_str_mv | AT wickspaul therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT rasouliyanlawrence therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT katicbo therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT nafeesbeenish therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT floodemuella therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT sasanerahul therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT wickspaul realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT rasouliyanlawrence realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT katicbo realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT nafeesbeenish realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT floodemuella realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis AT sasanerahul realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis |